Biodegradable intraocular therapies for retinal disorders: progress to date

Area of Science:

• Ophthalmology
• Biomedical Engineering
• Drug Delivery Systems

Background:

• Topical and systemic drug administration often fails to reach therapeutic concentrations in the vitreous and retina.
• There is a critical need for intraocular drug delivery systems offering sustained drug release and reduced administration frequency for vitreoretinal disorders.

Purpose of the Study:

• To review the progress of major biodegradable drug delivery systems for vitreoretinal disorders.
• To highlight systems currently in clinical trials or experimental stages.

Main Methods:

• Review of existing literature on intraocular drug delivery systems.
• Focus on biodegradable formulations including implants and injectable particles.
• Analysis of clinical trial and experimental stage devices.

Main Results:

• Several non-biodegradable implants are clinically available or in late development for conditions like CMV retinitis, uveitis, and diabetic macular edema.
• Biodegradable formulations (rods, plugs, discs, nanoparticles) are under investigation but not yet widely available.
• Ozurdex (dexamethasone intravitreal implant) is a key approved biodegradable option for retinal vein occlusion-related macular edema.

Conclusions:

• Biodegradable intraocular drug delivery systems show significant promise for treating various vitreoretinal disorders.
• Continued research and development are essential to bring these advanced delivery systems to clinical practice.
• Sustained intraocular drug delivery is crucial for improving patient outcomes in ophthalmology.